How Can We Help You?
At swii.ch, we help rare-disease teams turn insight into impact.
Whether you’re identifying patients, building advocacy or preparing for JCA, our work is designed to amplify patient voice, improve readiness and support confident access planning.
JCA Readiness
Prepare for EU JCA with confidence.
We support biopharma teams to:
- understand likely expectations
- align HQ, regions and affiliates
- organise patient insight early
- structure evidence inputs in a clear, traceable way
All through RAREready™, our modular JCA readiness framework designed specifically for rare-disease innovators.
Patient Identification
Find and engage the right patients earlier.
We combine behavioural science, digital tools and ethically grounded analysis to help sponsors identify hidden populations and accelerate diagnosis in rare disease.
Our work includes:
- behaviour-based patient journey mapping
- digital awareness and micro-segmentation
- co-designed outreach strategies with patient groups
- integration with clinical and advocacy networks
Advocacy & Education
Build trust. Strengthen awareness. Empower communities.
We co-create programmes with patient communities to:
- map digital and advocacy ecosystems
- design meaningful awareness and education initiatives
- support evidence literacy where appropriate
- develop practical materials for patients, caregivers and HCPs
Our approach centres collaboration, insight and shared decision-making.
Digital-first. Insight-led. Built for rare disease complexity.
At swii.ch, we go beyond traditional engagement. Our approach blends behavioural science, digital innovation, and strategic consultancy to solve the toughest challenges in rare disease. From cross-border coordination to patient co-creation, we design systems — not just services — that accelerate access, build trust, and deliver measurable impact.
What Our Clients Say
I have been engaging with swii.ch in the last 18 months to utilise their services in patient engagement and consultancy. Throughout this time, they have delivered to me qualitative analyses, patient group research and strategic advice, and will be supporting me with various patient and access-related activities.
I would not hesitate to recommend the team for their experience, counsel, transparency, delivery and ability to build good relationships with people both in and outside the company.
Vice President EMEA – Lupin Neurosciences
We chose to work with swii.ch as they demonstrated their unique approach of combining years of patient engagement experience with technical/digital competencies to ensure patients remain central to the solutions we develop.
At the time we were planning to develop a roadmap for our digital strategy for an ultra-rare neuromuscular disease, and the approach swii.ch recommended allowed us to develop a good understanding of the patient’s digital journey for information that enabled us to identify the gaps that exist in the specific disease area. Swii.ch effectively guided the team’s creative thinking around insights gathered through the first phase of the project which enabled us to deliver a plan to develop a structured digital ecosystem that we believe will empower patients and their families/caregivers with information and solutions to live their best lives.
Director of Patient Engagement and Advocacy EMEA Alnylam Pharmaceuticals Europe
Rare Insights
From JCA readiness to patient engagement, our team shares what’s working — and what’s next — in rare disease access.
JCA is underway…what it really means for rare disease evidence
Introduction This article first appeared in the Rare Focus newsletter on LinkedIn (October 2025). The EU Joint Clinical Assessment (JCA) is[…]
EU JCA 2025 Explained: What Rare Disease Sponsors Need to Know Now
The EU Joint Clinical Assessment (JCA) is one of the most significant changes to hit market access in years. Under Regulation (EU)[…]
AI, Rare Disease Research, and the Risks of “Synthetic Patients”
Artificial intelligence (AI) is beginning to find its place in rare disease research. With small populations, fragmented registries, and[…]